Want to see JP:3750 full AI Analyst Report?
Cytori Cell Research Institute, Inc. (3750) AI Stock Analysis
Cytori Cell Research Institute, Inc.
(TSE/TYO:3750)
The company faces existential financial risks with collapsing revenue, severe cash burn, and near-zero equity, which are the primary drivers of the low score. Technicals show a neutral but weak trend, and the negative P/E ratio confirms a lack of earnings power. The absence of dividends or positive catalysts further weighs on the outlook.
Cytori Cell Research Institute, Inc. (3750) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.14B
- Dividend Yield
- ―
- Average Volume (3M)
- 7,160
- Price to Earnings (P/E)
- -12.7
- Beta (1Y)
- 0.43
- Revenue Growth
- 15.47%
- EPS Growth
- 69.34%
- Country
- Japan
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cytori Cell Research Institute, Inc. Business Overview & Revenue Model
Company Description
Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cel...
How the Company Makes Money
null
Cytori Cell Research Institute, Inc. Financial Statement Overview
Summary
Severe financial distress: Revenue collapsed 42.6% in FY2026 after a 92% drop in FY2025, net losses persist, operating cash flow is deeply negative at -¥784.8M, and equity is nearly depleted at ¥22M. Debt elimination is the sole positive, but solvency risks are critical.
Income Statement
15Very NegativeBalance Sheet
20Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.58M | 50.99M | 122.20M | 1.56B | 2.14B | 1.34B |
| Gross Profit | 57.41M | 9.87M | -55.56M | 1.08B | 988.61M | 622.73M |
| EBITDA | -865.50M | -905.48M | -757.31M | -518.43M | -462.87M | -141.28M |
| Net Income | -560.36M | -396.90M | -2.14B | 138.16M | -1.06B | -77.63M |
Balance Sheet | ||||||
| Total Assets | 363.19M | 368.06M | 3.54B | 5.82B | 14.09B | 16.01B |
| Cash, Cash Equivalents and Short-Term Investments | 67.10M | 125.90M | 255.98M | 1.04B | 1.12B | 851.56M |
| Total Debt | 250.00M | 0 | 2.65B | 2.47B | 8.51B | 9.27B |
| Total Liabilities | 434.88M | 346.03M | 2.91B | 3.02B | 11.43B | 12.29B |
| Stockholders Equity | -71.69M | 22.02M | 630.54M | 2.79B | 2.65B | 3.71B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -784.77M | -995.12M | -1.17B | -198.04M | -367.83M |
| Operating Cash Flow | 0 | -784.77M | -987.04M | -1.15B | -39.52M | -187.78M |
| Investing Cash Flow | 0 | 2.98B | 22.90M | 8.69B | -283.06M | -216.19M |
| Financing Cash Flow | 0 | -2.32B | 171.65M | -7.17B | 294.23M | 35.80M |
Cytori Cell Research Institute, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Positive. The current price of 800.00 is above the 20-day moving average (MA) of 770.85, above the 50-day MA of 797.34, and below the 200-day MA of 821.72, indicating a neutral trend. The MACD of -5.92 indicates Negative momentum. The RSI at 59.12 is Neutral, neither overbought nor oversold. The STOCH value of 89.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3750.
Cytori Cell Research Institute, Inc. Peers Comparison
Overall Rating
JP:459348Neutral
JP:488045Neutral
JP:777442Neutral- JP:375040Underperform
JP:459938Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4880 | 45Neutral | JPY 5.68B | 57.55 | ― | 1.75% | -9.94% | ― |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:3750 | 40Underperform | JPY 7.14B | -12.75 | ― | ― | 15.47% | 69.34% |
| JP:4599 | 38Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3750 | Cytori Cell Research Institute, Inc. | 800.00 | -40.00 | -4.76% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4880 | CellSource Co., Ltd. | 286.00 | -225.00 | -44.03% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 18, 2026